Sleep Modulation to Treat Depression

Launched by CHRISTOPH NISSEN · May 29, 2024

Keywords

ClinConnect Summary

This clinical trial, titled "Sleep Modulation to Treat Depression," is investigating a new treatment approach for people with Major Depressive Disorder (MDD). Researchers want to explore how sleep patterns can be used to understand and potentially improve treatment for depression. The goal is to see if a new technology that focuses on sleep can help people feel better and understand how it works in the brain.

To be eligible for this study, participants must be adults diagnosed with MDD and able to provide written consent. Unfortunately, those with other serious mental health conditions, certain medical issues, or specific sleep disorders won't be able to join. If you participate, you can expect to undergo assessments related to sleep and depression, and you’ll be closely monitored throughout the trial. It’s an exciting opportunity that aims to find new ways to help those struggling with depression, especially since current treatments don’t work for everyone.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Written informed consent
• • MDD according to ICD-10 criteria (F32.1/2, F33.1/2; i.e. unipolar depression) for patient group
• Exclusion Criteria:
• • Relevant psychiatric disorders (other than MDD for the patient group), such as organic psychiatric disorders, lifetime history of substance dependency or current substance abuse (smoking will be allowed for recruitment reasons), schizophrenia or other psychotic disorders, affective disorders including bipolar disorder, borderline personality disorder, autism or other severe psychiatric disorders
• • Known pregnancy
• • Unstable medical conditions, such as unstable cardiovascular or metabolic disorders, etc.
• • Relevant neurological disorders, including epilepsy, stroke, etc.
• • Organic sleep disorders including relevant sleep apnea (AHI\>15/h), periodic limb movement disorder (PLMS index\>5/h), Restless-Legs-Syndrome (RLS), narcolepsy, circadian rhythm disorder or shift work/ jet lag
• • Intake of medication affecting the central nervous system (other than antidepressants and lithium in patients); patients receiving benzodiazepines or (es)ketamine will not be included
• • Current brain stimulation treatment, such as electroconvulsive therapy (ECT), TMS or deep brain stimulation
• • Contraindications for tDCS or TMS studies, including but not limited to metal in the head/ brain or epilepsy
• • Hearing impairment or tinnitus (auditory stimulation study)
• • Inability to follow the procedures of the study (for example due to language problems)
• • Left-handedness